Loading…
Loading grant details…
| Funder | NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES |
|---|---|
| Recipient Organization | Albert Einstein College of Medicine |
| Country | United States |
| Start Date | Sep 01, 2024 |
| End Date | Jun 30, 2029 |
| Duration | 1,763 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10863593 |
The overarching goal of the PROVIDENT consortium is to develop "plug-and-play" vaccine and therapeutic antibody blueprints for three major groups of emerging enveloped RNA viruses—nairoviruses, hantaviruses, and paramyxoviruses. PROVIDENT is organized into four Research Projects, supported by three Research Cores and a Data Management Core. The
Administrative Core, Core A, will serve as the hub for PROVIDENT, providing governance, personnel, and resources for all program management arms. Albert Einstein Colllege of Medicine (Einstein) will serve as the lead institution and bear overall responsibility for PROVIDENT. To achieve these goals and advance PROVIDENT’s strategic research plan, we will develop and
implement plans to: (1) organize, oversee, monitor, and report Center activities; (2) oversee and facilitate data sharing with the ReVAMPP Center network and the public; (3) foster team interaction and coordination; (4) communicate the Center's mission and activities to the scientific community and the public; and (5) manage travel, conflict, change, risk, intellectual property,
human subjects and animals, resources, reagents, and regulatory challenges.
Albert Einstein College of Medicine
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant